The Food and Drug Administration (FDA) issued a warning letter to NutraPharma, for selling false and misleading products that claim to treat addiction and chronic pain. The products are sold via the website nyloxin.com.
Treatment with buprenorphine-naloxone hydrochloride or extended-release naltrexone hydrochloride may not be associated with pain induction or aggravation of mild to moderate chronic pain.
Current policy interventions aiming to curb opioid-related deaths are unlikely to be effective in the coming years.
Drug overdoses resulted in approximately 72,000 deaths in the US, according to the CDC.
Drug poisoning deaths were found to be largely accidental and to continue to increase, particularly among white men.
Policies requiring prior authorization for high-dose opioid prescriptions were found to be effective in reducing the average daily opioid dose consumed.
A revised version of the Opioid Risk Tool was found to identify the risk for developing opioid use disorder in patients on long-term opioid therapy for chronic nonmalignant pain with high specificity and sensitivity.
The Food and Drug Administration (FDA) has granted Fast Track designation to nalmefene HCl injection (Purdue Pharma) for the emergency treatment of known or suspected opioid overdoses.
Since the early 2000s, the United States has had the highest drug overdose death rates among its peer countries.
Patient misuse of prescribed opioids was found to be associated with opioid use disorder, misuse of other drugs, history of illegal activity, and psychological distress.